Equity Overview
Price & Market Data
Price: $6.60
Daily Change: +$0.10 / 1.52%
Daily Range: $6.49 - $6.80
Market Cap: $716,484,352
Daily Volume: 2,514,737
Performance Metrics
1 Week: 9.44%
1 Month: 9.44%
3 Months: 474.8%
6 Months: 97.31%
1 Year: -25.14%
YTD: 113.9%
Company Details
Employees: 155
Sector: Health technology
Industry: Biotechnology
Country:
Details
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase 11 loss-of-function mutations for treating lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.